HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-18-2014, 02:03 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-

Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials.

Abstract No:
508
Attend this session at the
2014 ASCO Annual Meeting!


Session: Breast Cancer - HER2/ER
Type: Oral Abstract Session
Time: Saturday May 31, 3:00 PM to 6:00 PM
Location: N Hall B1
Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Ciara Catherine Maria O'Sullivan, Ian Bradbury, Evandro De Azambuja, Edith A. Perez, Priya Rastogi, Marc Spielmann, Heikki Joensuu, Karla V. Ballman, Joseph P. Costantino, Suzette Delaloge, Dimitrios Zardavas, Martine J. Piccart-Gebhart, JoAnne Zujewski, Eileen McCormick Holmes, Richard D. Gelber; National Cancer Institute, Bethesda, MD; Frontier Science, Kincraig, United Kingdom; Institut Jules Bordet, Brussels, Université Libre de Bruxelles, Brussels, Belgium; Mayo Clinic, Jacksonville, FL; University of Pittsburgh Medical Center, Pittsburgh, PA; Institut Gustave Roussy, Villejuif, France; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Mayo Clinic, Rochester, MN; Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; Institut de Cancerologie Gustave Roussy, Villejuif, France; Jules Bordet Institute, Breast International Group, Brussels, Belgium; Frontier Science (Scotland), Inverness-Shire, Scotland; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
Abstract Disclosures

Abstract:

Background: Adjuvant T plus chemotherapy improves disease-free survival (DFS) and overall survival (OS) vs. chemotherapy alone for pts with early stage HER2-positive breast cancer. We conducted a meta-analysis to estimate DFS and OS for pts with small tumors (≤2cm) in the T arms from 5 of the 6 randomized adjuvant trastuzumab trials. Pts with tumors ≤2cm, with 0 or 1 positive lymph nodes, and hormone receptor (HR) positive disease had a 5-year DFS of 91% and a 5-year OS of 97% (O’Sullivan, SABCS 2013; abstract:1327). We now plan to conduct an additional meta-analysis to assess the efficacy of T compared with no T for pts with small tumors (≤2cm). Methods: Six randomized controlled trials (RCT) were identified by a Medline search from 2004-2013. Trial groups from 5 phase III RCTs provided data (HERA, NCCTG N9831, NSABP B31, PACS 04, and FinHER).In total, 11,200 pts were randomized in these 5 trials;4,220 of whom had ≤2cm tumors, and known number of positive axillary lymph nodes and HR status(2,588 randomized to T and 1,632 to no T). The individual pt meta-analysis will include pts with tumors ≤2 cm (T1a, T1b and T1c) and 0-1, 2-3 and ≥ 4 positive lymph nodes. Separate analyses will be performed for the two HR cohorts. This analysis will complement the published summary data-based Cochrane Review (Moja et al. 2012) by allowing a detailed investigation of the effect of disease characteristics, such as HR, on treatment effects. In addition to the standard Yusuf-Peto fixed effects model (Yusuf et al. 1985) we will investigate the impact of heterogeneity in study baseline hazards and study treatment effects by fitting random effect models.An intention to treat approach will produce a conservative effect estimate as substantial numbers of control-group pts 'crossed over' to the T arm after positive DFS results were reported. Methods to account for this ‘selective crossover’ are being developed; we plan to extend these methods to the meta-analysis setting to provide less conservative estimates. Results: Pending. Conclusions: A meta-analysis of 5 randomized adjuvant T trials focusing on pts with tumors ≤2cm will be performed and results submitted before the meeting.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 11:39 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter